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Atrial Fibrillation Ablation Using a
Robotic Catheter Remote Control System
Initial Human Experience and Long-Term Follow-Up Results
Walid Saliba, MD,* Vivek Y. Reddy, MD,† Oussama Wazni, MD,* Jennifer E. Cummings, MD,*
J. David Burkhardt, MD,* Michel Haissaguerre, MD,‡ Josef Kautzner, MD,§ Petr Peichl, MD,§
Petr Neuzil, MD,# Volker Schibgilla, MD, Georg Noelker, MD, Johannes Brachmann, MD,
Luigi Di Biase, MD,*¶ Conor Barrett, MD,* Pierre Jais, MD,‡ Andrea Natale, MD, FACC, FHRS**††‡‡
Cleveland, Ohio; Boston, Massachusetts; Bordeaux, France; Prague, Czech Republic; Coburg, Germany;
Foggia, Italy; Austin, Texas; and Palo Alto, California
Objectives We present the initial clinical human experience with the use of a robotic remote navigation system (Hansen
Medical, Mountain View, California), to perform left and right atrial mapping and radiofrequency ablation of
atrial fibrillation (AF) and atrial flutter (AFL).
Background Catheter ablation is an established curative modality for various arrhythmias. A robotic steerable sheath system
(SSS) (Hansen Medical) allows better catheter stability and greater degrees of freedom of catheter movement.
Methods A total of 40 patients (mean age 57 years) with antiarrhythmic drug (AAD)–refractory AF (23 had also concomitant
documented typical AFL) were studied. Three-dimensional reconstruction of the corresponding atrial chamber anat-
omy was performed with the CARTO electroanatomic mapping system (Biosense Webster, Diamond Bar, California or
the EnSite NavX system (St. Jude Medical, Minneapolis, Minnesota) in combination with the Artisan catheter (Hansen
Medical). In patients undergoing AF ablation, 2 transseptal punctures were performed under intracardiac ultrasound
(ICE) guidance, with one of the punctures being performed using SSS. Pulmonary vein antrum isolation was per-
formed with a 3.5-mm thermocool catheter manipulated with the use of the SSS and was verified by circular map-
ping. Patients were followed clinically for recurrence of arrhythmia with an event transmitter and ambulatory holter
monitoring. Clinical recurrence of AF/AFL was defined as AF/AFL episodes1 min in duration.
Results Pulmonary vein antrum isolation was performed in 40 patients, including 23 with concomitant typical AFL abla-
tion. All pulmonary veins, including the superior vena cava, were successfully isolated. In 23 of 40 patients,
cavotricuspid ablation was also performed with bidirectional block obtained. At 1-year follow-up, 34 patients
(86%) and 5 patients were free from atrial arrhythmia off AADs and on AADs, respectively.
Conclusions This preliminary human experience suggests that mapping and ablation of AFL and AF using this novel robotic
catheter with remote control system is feasible with similar results to conventional approach. (J Am Coll
Cardiol 2008;51:2407–11) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.027C
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008, accepted March 4, 2008.atheter ablation has been established as a successful
urative modality for various kinds of tachyarrhythmias
1,2). Specifically, the various techniques for catheter-based
blation of atrial fibrillation (AF) are evolving rapidly. Ablation
argets include anatomic ablation, electrogram-based ablation,
nd the creation of circular ablation lesion sets around the
See page 2412
ulmonary veins (PVs) together with placement of linear
blation lesions in the atria (3–7). However, regardless of
trategy, the safety and success of these approaches is operator
ependent and require precise catheter manipulation and stable
ontact during ablation energy delivery.
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Robotic Catheter Atrial Fibrillation Ablation June 24, 2008:2407–11We have previously reported
our experience showing the safety
and feasibility of endocardial cath-
eter navigation and mapping by
using a robotic catheter remote
control system in dogs (8). The
aim of this study was to evaluate
the safety and efficacy of a robotic
steerable guide catheter to perform
radiofrequency ablation in the
treatment of AF and atrial flutter
(AFL) in humans.
Methods
This is a prospective multicenter
study. Patients with symptomatic
F with or without documented AFL who had failed at
east one antiarrhythmic medication were considered for
nrollment. At 12 months after ablation, the data were
eviewed and analyzed. Enrollment occurred in 3 centers in
urope: Prague, Coburg, and Bordeaux.
Patients were eligible to enter the study if they had
xperienced symptomatic AF episodes for 3 months and
ad failed to respond to at least 1 antiarrhythmic medica-
ion. Patients with the following criteria were excluded: 1)
ge 18 and 75 years; 2) previous history of AFL or AF
blation; 3) previous history of open-heart surgery; or
) contraindication for long-term anticoagulation treat-
ent. Each patient signed an informed consent approved
y the institutional ethic committee at the corresponding
ospital. Forty patients were enrolled in the study. The end
oints of the study were feasibility of isolation of the PVs
nd superior vena cava (SVC), achieving bidirectional isthmus
lock in patients with concomitant typical AFL, and the re-
urrence of arrhythmia in patients at 12 months after ablation
hile they were not receiving antiarrhythmic drugs (AADs).
obotic system. The robotic system (SenseiRobotic Cath-
ter System, Hansen Medical, Mountain View, California)
onsists of a physician workstation that includes the instinc-
ive motion controller (Fig. 1), a remote catheter manipu-
ator (Fig. 1), and a setup joint that is mounted on a table at
he patient’s side. The remote catheter manipulator directly
ontrols a robotic hollow catheter (Artisan Catheter, Han-
en Medical) consisting of an internal steerable guide sheath
ystem (SSS, Artisan Catheter) (Fig. 1). This robotic hollow
atheter is in reality a hollow robotically steered sheath that
an house any mapping or ablation catheter. The physician
orkstation is placed at a remote location from the patient’s
able. The control is provided via a master and slave
lectromechanical system: the operator movements at the
nstinctive motion controller (Fig. 1) are updated constantly
ith resultant seamless motion of the catheter (Fig. 1).
sing this system, the operator can perform catheter control
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
AFL  atrial flutter
CT  computed
tomography
ICE  intracardiac
echocardiography
PV  pulmonary vein
SSS  steerable sheath
system
SVC  superior vena cava
3D  three-dimensionaln 3 dimensions and also allows for tight bend radius. Ahree-dimensional (3D) mapping. Mapping was done in
n effort to study the potential integration of this robotic
ystem with available mapping systems. In all patients, 3D
econstruction of the corresponding atrial chamber anatomy
as performed with the CARTO electroanatomic mapping
ystem (Biosense Webster, Diamond Bar, California; 22
atients) or the EnSite NavX system (St. Jude Medical,
inneapolis, Minnesota; 18 patients) (Fig. 1). Registration
ith the 3D computed tomography (CT) was performed in
atients in whom CARTO was used and side-by-side
ynchronization was performed in the cases where NAvX
as used.
rocedure. Patients were brought to the electrophysiology
aboratory in the post absorptive state. A multipolar catheter
as placed into the coronary sinus. The Acunav (Siemens
cuson, Mountain View, California) intracardiac echocar-
iography (ICE) catheter was placed via the left femoral
ein and was positioned in the right atrium. This placement
as used to facilitate catheter manipulation, monitor circular
apping catheter position, and guide transseptal puncture.
After manually placing the SSS in the inferior right
trium, the position of the SSS was registered into the
obotic catheter remote control system. This registration
nvolved the use of 2 orthogonal fluoroscopic views of the
eart (anterior-posterior and lateral) to allow the saving the
osition of the SSS in 3D space.
F ablation. The SSS was inserted via a 14-F sheath in the
ight femoral vein and advanced manually into the right
trium under fluoroscopic visualization. In patients under-
oing AF ablation, 2 transseptal punctures were performed
nder ICE guidance. The first transseptal puncture was
erformed manually. We used ICE to confirm the appro-
riate puncture site. Through this transseptal puncture, a
ong sheath was advanced into the left atrium, and a circular
apping catheter was introduced into the left atrium. We
erformed the second transseptal puncture with the Sensei
ystem by using a transseptal sheath and dilator (Hansen
edical, Inc.); a custom-made transseptal needle (Hansen
edical, Inc.) was advanced through a dilator lumen.
After the septum was punctured, the SSS and dilator
ere advanced robotically in the LA and the dilator replaced
ith a 3.5-mm thermocool catheter (Navistar, Biosense-
ebster) that was then inserted into the SSS with approx-
mately 1 cm of the ablation catheter exposed (Fig. 1). This
atheter was used for ablation. Systemic anticoagulation was
nitiated just before the first transseptal puncture with the
se of intravenous heparin with a target ACT of approxi-
ately 400 s. A fixed radius decapolar Biosense LASSO
ircular mapping catheter (Biosense Webster) was used for
apping the PV antra. With this configuration, the final
etup before initiation of ablation included the following: A
obotically controlled steerable sheath housing the ablation
atheter (this is performed by a physician at the console) and
manually controlled circular mapping catheter handled
nd moved by a second physician at the procedure tableside.
blation along the PV’s antrum, which encompasses the
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June 24, 2008:2407–11 Robotic Catheter Atrial Fibrillation Ablationosterior wall and septal portions of the right PVs, was
erformed with the Artisan robotic system until disappear-
nce of local PV potential with the end point of electrical
solation of all PV antra as well as SVC isolation at the level
f the SVC-right atrial junction.
Radiofrequency power was set at 30 W with a maximum
emperature limit of 45°C with irrigation using heparinized
aline infusion (2,000 IU/l) at a rate of 30 ml/min via the
ool Flow pump (Biosense Webster). At the end of the
rocedure, systemic anticoagulation was discontinued and
artially reversed with intravenous protamine before re-
oval of vascular sheaths. Three months after ablation, all
atients underwent a CT scan so that they could be
xamined for the presence of PV stenosis.
F ablation. After PV and SVC isolation were performed,
he circular ablation catheter was withdrawn. Ablation along
he posterior cavotricuspid isthmus was performed in 23
atients with the robotic system in conjunction with the
.5-mm thermocool catheters (Navistar, Biosense-Webster).
idirectional block was confirmed with 3D mapping and
roximal coronary sinus/posteriolateral right atrial pacing.
ollow-up. Follow-up was scheduled at 1, 3, 6, and 12
onths. An event recorder was used in all patients to
onitor events during the first month and was repeated at
months. During the monitoring period, patients were
sked to record any symptoms and once weekly, even if they
ere asymptomatic. Additional event recorder monitoring
as considered beyond the 3-month period for patients
ith recurrence of symptoms. All patients had a spiral CT
can after 3 months. Patients resumed oral anticoagulation
herapy with warfarin on the evening of the procedure and
ral anticoagulation therapy was continued for at least 6
onths. Antiarrhythmic drugs were continued for a
-month period. A 2-month blanking period was used in
hich episodes of AF occurring within that time period
ere not considered procedure failures.
esults
tudy population. Between January 2005 and July 2006,
0 patients were enrolled in the study. The characteristics of
he study population are described in Table 1. A total of 40
atients (29 men/11 women, mean age 57  20 years) with
F were included in this study. Twenty-three patients also
ad documented typical AFL. These patients had failed to
espond to an average of 2  1 AADs. The mean left
entricular ejection fraction was 58  12%. Atrial fibrilla-
ion was paroxysmal in 75% and recently persistent in 25%.
Pulmonary vein antrum isolation (which includes abla-
ion along the posterior wall and septal aspect of the right
Vs) was performed in 40 patients. Concomitant AFL
blation was also performed in 23 of these 40 patients. All
Vs in addition to the SVC were successfully isolated.
All ablations were performed with the robotic system. The
rocedure was assessed using fluoroscopy and also imageFigure 1 The Sensei Robotic Catheter System
The entire system is depicted. (A) The workstation, including the master
consol, is mobile and can be moved to an area remote from the patient and
fluoroscopy. It can depict electrograms, intracardiac echo images, fluoros-
copy, and also 3-dimensional navigation images. The instinctive motion con-
troller device is located on the master consol. The physician operator
maneuvers the handle guided by the images on the consol (intracardiac
echocardiography, fluoroscopy, and electroanatomical maps) to guide the
catheter within the body. (B) The remote catheter manipulator (RCM) is
mounted to the tableside and connected to the catheter, which is placed
inside the cardiovascular system. Movement of the instinctive motion con-
troller is transmitted by the use of motion logic to the RCM, which in turn
maneuvers the catheter. The RCM mounts at the bedside and directs the
catheter using the steerable catheter/sheath units. With the use of inter-
preted motion logic, it is able to smoothly transmit the operator’s motions
of the master input device to the catheter. The Artisan steerable sheath
system consists of a steerable guide catheter inside a steerable sheath,
which allows the transmission of the operator’s movements (via the RCM)
to direct the catheter. This complex system allows for motion in 3 dimen-
sions in response to the operator’s hand motion.ntegration with CARTO and NAvX. Total procedure time
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Robotic Catheter Atrial Fibrillation Ablation June 24, 2008:2407–11as 163  88 min, ablation time was 89.6  43 min, and
uoroscopy time was 64  33 min (Table 2). The average
adiation exposure at the procedure table was 149 versus 13
icroseiverts at the physician workstation (p  0.05).
rocedural complications. Two patients undergoing pul-
onary vein isolation developed pericardial tamponade
equiring pericardiocentesis with no other sequelae (proce-
ure was aborted in one patient after manual transseptal).
ong-term follow-up. At 12 months follow-up, 34 pa-
ients were free from atrial arrhythmia off AADs and 5 were
rrhythmia free on previously ineffective AADs. No patients
eveloped PV stenosis.
iscussion
his report demonstrates the safety of robotically performed
ransseptal puncture in addition to atrial ablation for AF
nd AFL. The efficacy is similar to results reported with the
se of the conventional approach. Furthermore, there does
ot appear to be any increased risk of perforation or
ntracardiac damage associated with this remote naviga-
ional system.
linical importance of remote control. Endocardial navi-
ation by the use of conventional manual steerable diagnostic
nd ablation catheters and transseptal puncture by the use of
tandard equipment can be challenging and time consuming.
his challenge is partly related to the variability of the cardiac
natomy as well as operator’s skills and experience in catheter
avigation. This remote robotic manipulation system offers an
pportunity to overcome the limitations of manual control. In
ddition, it provides precise as well as stable positioning, which
ould potentially improve the efficacy and safety of ablation
rocedures. In this case series, the robotic console was close to
he table because of space constraints. Specifically designed
lectrophysiologic laboratory space can allow accommodation
f the robotic console in a location away from radiation.
aving the physician in a remote area at the workstation will
educe the physician’s radiation exposure during long proce-
ures of electrophysiologic study and catheter ablation. Also, in
ur case series where we used a strategy of verification of
solation with the circular mapping catheter, there was a need
or a second physician to manipulate the mapping catheter at
he bedside. With the use of other strategies, such as anatom-
cally based ablation, there would be no need for a separate
aseline Demographics of Patients (n  40)
Table 1 Baseline Demographics of Patients (n  40)
Age, yrs, mean  SD 57  8
Left atrial size, cm, mean  SD 4.1  0.8
Duration of AF, months, mean  SD 48  12
Paroxysmal AF 29
Recently persistent AF 11
Structural heart disease/hypertension 10% (10/40)
Ejection fraction, %, mean  SD 58  12
F  atrial fibrillation.apping catheter. In the future, it is possible that both theblation and mapping catheter can be controlled in tandem
ith 2 coordinated robotic steerable guides.
In contradistinction to the magnetic navigation system
hat requires specific compatible magnetic-guided catheters,
he robotic system is an open platform system whereby any
apping or ablation catheter of appropriate size can be
ntroduced into the remotely steerable catheter/sheath. The
agnetic navigation system requires continuous alteration
nd adjustment of the magnetic field and then advancement
f the catheter in that direction. With the use of this system,
continuous uninterrupted motion of the ablation catheter
an be achieved with the use of the instinctive motion
ontroller (9–14).
adiation exposure. Because of the remote location of
he workstation from the fluoroscopy, radiation exposure
o the physician is significantly reduced. Our early
xperience showed an average of 12-fold reduction in
adiation dosage between a bedside dosimeter and one
ocated at the workstation, 3 to 4 m away. Again, as noted
arlier, the workstation was close because of space con-
traints. This difference will be more prominent as the
orkstation is moved further away to the control room, out
f the actual procedure room. Experience with other remote
avigation system using remote magnetic navigation
howed similarly a substantial reduction in radiation dose at
he control station. Furthermore, because of better catheter
tability and easier navigation with the robotic system, total
uoroscopy time and radiation exposure might be reduced;
owever, further head to head studies are needed to be able
o answer this question (9–14).
verall safety. There was one incidence of pericardial
ffusion related to the ablation procedure. This procedure
as done with a thermocool catheter, with flow rates at 30
l/min and power at 50 W resulting in a steam pop. The
ericardial effusion occurred after PV isolation and while
he operator ablated along the roof of the posterior wall with
reater power than specified. We believe that, with better
atheter contact and stability offered by the system, the
ffectiveness of ablation is increased, and one would need to
educe flow rates and maximum power in these situations.
urther studies will be needed to evaluate the optimum
blation energy parameters while using a robotic system at
ifferent pressure levels and compare those to the parame-
ers used with conventional manually operated catheters.
uch a contact pressure sensor has been developed by the
anufacturer (Intellisense, Bothell, Washington) and is
urrently being tested. This sensor was not available at the
ime of our study, but it will allow for the further evaluation
rocedural Parametersesults for the Robotic System
Table 2 Procedural ParametersResults for the Robotic System
Duration, min Total Atrial Fibrillation Atrial Flutter
Procedure time 163 88 189 88 126 56
Ablation time 89.6 43 106 25 56 54Fluoroscopy time 64 33 83 15 37 35
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June 24, 2008:2407–11 Robotic Catheter Atrial Fibrillation Ablationf adequate and optimal tissue contact during navigation
apping and ablation. The second incidence of pericardial
ffusion was not related to ablation or the robotic system
nd occurred with the manual transseptal puncture.
tudy limitations. In the present study, we did not compare
he mapping time using the computer-controlled system to the
urrent conventional manual method. Furthermore, the pro-
edural timing reported in the current study reflects our initial
ttempts and might be expected to improve with the further
xperience of the operator with the system. A larger series and
lso longer follow-up will be needed to further assess the safety
nd efficacy of this technology.
onclusions
his preliminary human experience suggests that mapping and
blation of AFL and AF with the use of this novel robotic
atheter with remote control system is feasible, with similar
esults compared with the conventional approach. Further-
ore, the use of the robotic catheter remote control system for
ransseptal puncture and endocardial navigation is safe and
easible. With improved catheter stability and contacts with
uch systems, more investigation is needed to evaluate whether
ifferent energy output parameters are needed as compared to
anual and conventional ablation catheters. Moreover, its
sefulness in decreasing procedure time and improving proce-
ural success compared with current approaches requires fur-
her evaluation in randomized clinical trials. Also in the future,
comparison between this technology and remote magnetic
avigation may be warranted.
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